



Press Release

ADIA invests in continuation vehicle for GL Capital's SciClone Pharmaceuticals

Abu Dhabi, UAE – 29 September 2025

A wholly owned subsidiary of the Abu Dhabi Investment Authority (“ADIA”) has acted as lead investor in the establishment of a single-asset continuation vehicle for GL Capital’s SciClone Pharmaceuticals (“SciClone”).

Since GL Capital’s initial investment in 2012, SciClone has grown into a leading China-focused specialist pharmaceutical company focused on oncology and immunity.

The continuation vehicle allows GL Capital to retain control of SciClone and continue to scale the company’s commercial operations, advance its pipeline execution and pursue selective business development opportunities.

Hamad Shahwan Aldhaheri, Executive Director of the Private Equities Department at ADIA, said: “SciClone is a market leading business that is well-positioned to benefit from long-term structural trends in China’s healthcare sector. This investment alongside GL Capital reflects our ability to back high-conviction opportunities alongside experienced managers with a proven track record of value creation.”

--- ENDS ---

ABOUT ADIA

Established in 1976, the Abu Dhabi Investment Authority (“ADIA”) is a globally-diversified investment institution that prudently invests funds on behalf of the Government of Abu Dhabi through a strategy focused on long-term value creation.

For more information:

[https://www.adia.ae](http://www.adia.ae)

Abu Dhabi
Investment Authority
211 Corniche Street,
PO Box 3600
Abu Dhabi,
United Arab Emirates
T +971 2 415 0000
F +971 2 415 1000
www.adia.ae



For further details, please contact:

Garry Nickson
Abu Dhabi Investment Authority
T: +971 2 415 6085
E: Garry.Nickson@adia.ae